Afriplex cannabis footprint continues to expand

Afriplex, a proud member of the ImpiloVest Group, recently entered into a joint technology agreement with a Canadian partner for the development and manufacturing of CBG.

The partnership will see CBG Isolate provided to Afriplex’s international customers, expanding its already extensive portfolio of cannabinoid offerings.

According to Arno Roux, Managing Director of Afriplex, new advancements and understanding in cannabinoid therapies can be beneficial in allowing the market to continue to grow and for patient benefit.

He says: “As Afriplex we are proud to continue pushing the boundaries in cannabis. This partnership once again allows us to be a preferred partner for businesses looking to enter the market or establish their products in the market. While regulations in South Africa remain prohibitive for CBG, we are excited to provide this offering to our international clientele, while we eagerly await for a better regulatory framework from a local perspective.” 

Cannabigerol, or CBG, is a non-psychoactive cannabinoid found in cannabis. While it may not be as well-known as THC or CBD, CBG has been gaining attention in the cannabis industry for its potential therapeutic benefits. CBG is often referred to as the “mother cannabinoid” because it is the precursor to THC, CBD, and other cannabinoids. As the cannabis plant grows, CBG is converted into these other cannabinoids through a process called biosynthesis. Research on CBG is still in its early stages, but preliminary studies have suggested that it may have a range of therapeutic uses.

Some of the potential benefits of CBG include:

  1. Anti-inflammatory properties: CBG has been shown to have powerful anti-inflammatory properties, which may make it useful in treating conditions like arthritis and inflammatory bowel disease.
  2. Pain relief: CBG may also have analgesic properties, making it potentially useful for managing pain.
  3. Neuroprotective effects: Some studies have suggested that CBG may have neuroprotective effects, which could make it useful in treating conditions like Parkinson’s disease and multiple sclerosis.
  4. Antidepressant effects: CBG has been shown to have antidepressant effects in animal studies, which could make it a useful treatment for depression and other mood disorders.
  5. Antibacterial properties: CBG has also been found to have antibacterial properties, which could make it useful in treating infections.

While research on CBG is still ongoing, there is growing interest in the potential therapeutic benefits of this cannabinoid. In addition to its potential therapeutic uses, CBG may also have commercial applications in the production of other cannabinoids. As the precursor to THC and CBD, CBG can be used to create strains of cannabis with higher levels of these cannabinoids.

Visit the official COVID-19 government website to stay informed: